Dominique Levêque

3.0k total citations
91 papers, 2.4k citations indexed

About

Dominique Levêque is a scholar working on Oncology, Pharmacology and Pharmacology. According to data from OpenAlex, Dominique Levêque has authored 91 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 18 papers in Pharmacology and 15 papers in Pharmacology. Recurrent topics in Dominique Levêque's work include Cancer Treatment and Pharmacology (23 papers), Drug Transport and Resistance Mechanisms (16 papers) and Antibiotics Pharmacokinetics and Efficacy (14 papers). Dominique Levêque is often cited by papers focused on Cancer Treatment and Pharmacology (23 papers), Drug Transport and Resistance Mechanisms (16 papers) and Antibiotics Pharmacokinetics and Efficacy (14 papers). Dominique Levêque collaborates with scholars based in France, Switzerland and Netherlands. Dominique Levêque's co-authors include F. Jehl, Raoul Herbrecht, Yasmine Nivoix, A. Astier, Nicolas Widmer, Étienne Chatelut, Christophe Bardin, Angélo Paci, Gareth J. Veal and Jos H. Beijnen and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Lancet Oncology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Dominique Levêque

89 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dominique Levêque France 27 773 534 343 342 325 91 2.4k
Walid M. Awni United States 30 528 0.7× 489 0.9× 602 1.8× 416 1.2× 425 1.3× 139 3.0k
Michel Tod France 35 891 1.2× 686 1.3× 530 1.5× 492 1.4× 564 1.7× 218 4.0k
Antonello Di Paolo Italy 34 1.4k 1.8× 1.1k 2.2× 227 0.7× 376 1.1× 410 1.3× 141 3.6k
Richard A. Robson New Zealand 29 388 0.5× 480 0.9× 270 0.8× 184 0.5× 489 1.5× 87 2.8k
John H. Rodman United States 27 455 0.6× 422 0.8× 837 2.4× 324 0.9× 219 0.7× 66 2.4k
Gareth J. Veal United Kingdom 32 1.0k 1.3× 1.3k 2.5× 615 1.8× 391 1.1× 310 1.0× 136 3.7k
Christopher Banfield United States 30 515 0.7× 328 0.6× 411 1.2× 196 0.6× 301 0.9× 88 2.8k
Ron J. Keizer Netherlands 20 364 0.5× 350 0.7× 295 0.9× 254 0.7× 306 0.9× 60 2.0k
Frank LaCreta United States 38 698 0.9× 1.1k 2.1× 188 0.5× 138 0.4× 373 1.1× 110 4.5k
D H Ho United States 27 768 1.0× 887 1.7× 205 0.6× 317 0.9× 308 0.9× 100 2.5k

Countries citing papers authored by Dominique Levêque

Since Specialization
Citations

This map shows the geographic impact of Dominique Levêque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dominique Levêque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dominique Levêque more than expected).

Fields of papers citing papers by Dominique Levêque

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dominique Levêque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dominique Levêque. The network helps show where Dominique Levêque may publish in the future.

Co-authorship network of co-authors of Dominique Levêque

This figure shows the co-authorship network connecting the top 25 collaborators of Dominique Levêque. A scholar is included among the top collaborators of Dominique Levêque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dominique Levêque. Dominique Levêque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Levêque, Dominique, et al.. (2023). Oral anticancer agents as generators of relevant pharmacokinetic interactions. Bulletin du Cancer. 110(6). 676–684. 2 indexed citations
2.
Nivoix, Yasmine, Guy Launoy, P. Lutun, et al.. (2017). Assessment of high-priced systemic antifungal prescriptions. Médecine et Maladies Infectieuses. 47(6). 382–388. 3 indexed citations
3.
Levêque, Dominique. (2016). SynthèseMédicaments biosimilaires en oncologieBiosimilar drugs in oncology. Bulletin du Cancer. 103(3). 2 indexed citations
4.
Widmer, Nicolas, Christophe Bardin, Étienne Chatelut, et al.. (2014). Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies. European Journal of Cancer. 50(12). 2020–2036. 240 indexed citations
5.
Nivoix, Yasmine, P. Kehrli, J. Gaudias, et al.. (2014). Pharmacie clinique et chirurgie : revue de la littérature. Annales Pharmaceutiques Françaises. 72(3). 152–163. 5 indexed citations
6.
Nivoix, Yasmine, et al.. (2013). Augmentation de l’activité anticoagulante de la fluindione par le miconazole en comprimé muco-adhésif. Journal de Pharmacie Clinique. 32(4). 251–254. 1 indexed citations
7.
Levêque, Dominique, et al.. (2012). Duration of adjuvant trastuzumab treatment in routine practice.. PubMed. 32(10). 4585–8. 11 indexed citations
8.
Nivoix, Yasmine, Guy Launoy, P. Lutun, et al.. (2012). Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. Journal of Antimicrobial Chemotherapy. 67(10). 2506–2513. 70 indexed citations
9.
Levêque, Dominique, et al.. (2011). Pharmacokinetic drug–drug interactions with methotrexate in oncology. Expert Review of Clinical Pharmacology. 4(6). 743–750. 50 indexed citations
10.
Levêque, Dominique & F. Jehl. (2007). Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids. The Journal of Clinical Pharmacology. 47(5). 579–588. 53 indexed citations
11.
Levêque, Dominique, et al.. (2005). La radio-immunothérapie des cancers. Journal de Pharmacie Clinique. 24(3). 139–144. 1 indexed citations
12.
Levêque, Dominique. (2003). Propriétés pharmacocinétiques des anticorps monoclonaux. Journal de Pharmacie Clinique. 21(4). 271–277. 1 indexed citations
13.
Steinmetz, A., et al.. (2003). À propos d'un cas de traitement de la papillomatose laryngée récidivante par injections intralésionnelles de cidofovir (Vistide®). Journal de Pharmacie Clinique. 21(4). 287–290. 1 indexed citations
14.
Levêque, Dominique, et al.. (2002). Rifampicine et P-glycoprotéine : un nouveau mécanisme d'interaction pharmacocinétique. Journal de Pharmacie Clinique. 20(4). 219–223. 1 indexed citations
15.
Salmon, J., et al.. (1997). Interest of use of miniature pig in pharmacokinetic studies. Journal de Pharmacie Clinique. 16(4). 3 indexed citations
16.
Limacher, Jean‐Marc, Dominique Levêque, Brigitte Duclos, et al.. (1997). Pharmacokinetics of high-dose doxorubicin administered as a 6-h intravenousinfusion in breast cancer patients. Bulletin du Cancer. 84(6). 2 indexed citations
17.
Salmon, Jean, et al.. (1997). Intérêt de l’utilisation du porc miniature dans les études pharmacocinétiques. Journal de Pharmacie Clinique. 16(4). 219–223. 1 indexed citations
18.
Levêque, Dominique, F. Jehl, Élisabeth Quoix, & H. Monteil. (1993). Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. Xenobiotica. 23(11). 1325–1333. 13 indexed citations
19.
Levêque, Dominique, F. Jehl, Élisabeth Quoix, & F. Breillout. (1992). Clinical Pharmacokinetics of Vinorelbine Alone and Combined with Cisplatin. The Journal of Clinical Pharmacology. 32(12). 1096–1098. 24 indexed citations
20.
Jehl, F., Élisabeth Quoix, Dominique Levêque, et al.. (1991). Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.. PubMed. 51(8). 2073–6. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026